SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA]
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: James Silverman who wrote (137)2/12/1997 3:33:00 AM
From: John Zwiener   of 1115
 
This is a nucleoside analog, one of the class of drugs, that will have a big impact on various diseases. Because it acts at the DNA level and interferes with DNA replication, I suspect there will be limited approval for a while until the potential side effects can be determined, if any. This would be a prudent and expected measure. Lidakol will have it's chance if it works. If Famvir does eventually show it has zero side effects in a few years, maybe more, then it will be a good choice for patients that are otherwise healthy. In the meantime, approval would probably be granted for immunosuppressed patients where the risk of not treating in these patients is significant. I understand this drug has shown early promising results in other viral disorders, such as hepatitis B.

Also, many people will be worried about very long term effects of messing with DNA, so a drug like Lidakol will continue to have a significant niche for decades (unless a vacine comes along).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News